{"id":544,"date":"2024-01-12T09:35:48","date_gmt":"2024-01-12T09:35:48","guid":{"rendered":"https:\/\/www.agb.nmuweb.com\/?page_id=544"},"modified":"2025-05-20T12:01:53","modified_gmt":"2025-05-20T12:01:53","slug":"transparency","status":"publish","type":"page","link":"https:\/\/www.agb.nmuweb.com\/se-eng\/transparency\/","title":{"rendered":"transparency"},"content":{"rendered":"\n\n\t\t\t\t\n\t\t\t\t\"agb_logo_green\"\n\t\t\t\t<\/a>\n\t\t\t\t\t\t
SWEDEN – ENG<\/h5>\n\t\t\t

SWEDEN<\/a>
UK<\/a>
NORWAY<\/a>
DENMARK<\/a>
GERMANY<\/a>
<\/p>\n\t\t\t\t\"border2\"\n

\n\t\tTransparency\n\t<\/h1>\n\t

EFPIA Disclosure Code Reports<\/b><\/h3>\n

AGB-Pharma discloses Transfers of Value to HCP’s and HCO’s in accordance with its commitment to the EFPIA Disclosure Code and the relevant local codes of practice and\/or local legal requirements, and in accordance with all applicable data protection laws and regulations.<\/p>\n

AGB-Pharma is responsible for publishing Disclosure Reports for countries in Europe in which it operates, to strengthen the public trust in the relationships between pharmaceutical companies and HCPs and HCOs.<\/p>\n

Please choose a country below to access the individual country reports.<\/p>\n\t\t\t\t\t\t

Sweden<\/h5>\n

Documentation<\/b><\/p>\n

Methodological Note (2022)<\/a>
Sweden Transfer of Value Report (2022)<\/a><\/p>\n

Methodological Note (2023)<\/a>
Sweden Transfer of Value Report (2023)<\/a><\/p>\n

Methodological Note (2024)<\/a>
Sweden Transfer of Value Report (2024)<\/a><\/p>\n\t\t\t\t\t\t

Denmark<\/h5>\n

Documentation<\/b><\/p>\n

Methodological Note (2022)<\/a>
Denmark Transfer of Value Report (2022)<\/a><\/p>\n

Methodological Note (2023)<\/a>
Denmark Transfer of Value Report (2023)<\/a><\/p>\n

Methodological Note (2024)<\/a>
Denmark Transfer of Value Report (2024)<\/a><\/p>\n\t\t\t\t\t\t

Norway<\/h5>\n

Documentation<\/b><\/p>\n

Methodological Note (2022)<\/a>
Norway Transfer of Value Report 2022<\/a><\/p>\n

Methodological Note (2023)<\/a>
Norway Transfer of Value Report (2023)<\/a><\/p>\n

No Transfers of Value have been made 2024<\/i><\/p>\n\t

Personal Data Policy<\/a>\u00a0 |\u00a0 Transparency<\/a>\u00a0 |\u00a0 Cookie Policy<\/a>\u00a0 |\u00a0 Contact<\/a><\/p>\n\tSE-MEL-AGB 0103 05\/2025
\n\u00a9 2024 AGB-Pharma AB. Last reviewed 05\/2025\n\t\t\t\t\"logo_forskandelakemedelsforetagen\"\n\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-544","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/www.agb.nmuweb.com\/se-eng\/wp-json\/wp\/v2\/pages\/544","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.agb.nmuweb.com\/se-eng\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.agb.nmuweb.com\/se-eng\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.agb.nmuweb.com\/se-eng\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.agb.nmuweb.com\/se-eng\/wp-json\/wp\/v2\/comments?post=544"}],"version-history":[{"count":0,"href":"https:\/\/www.agb.nmuweb.com\/se-eng\/wp-json\/wp\/v2\/pages\/544\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.agb.nmuweb.com\/se-eng\/wp-json\/wp\/v2\/media?parent=544"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}